Psyence Biomedical (PBM) Depreciation & Amortization (CF) (2024 - 2025)
Psyence Biomedical (PBM) recorded quarterly Depreciation & Amortization (CF) of -$1330.0 in Q3 2025, down 230.91% quarter-over-quarter from $1016.0 in Q3 2024, and down 230.91% on a YoY basis from $1016.0 in Q3 2024.
Psyence Biomedical (PBM) Depreciation & Amortization (CF) (2024 - 2025) Analysis & Trends
Psyence Biomedical's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at -$1330.0 for Q3 2025.
- In Q3 2025, Depreciation & Amortization (CF) fell 230.91% year-over-year to -$1330.0; the TTM figure through Sep 2025 stood at -$314.0 (changed N/A YoY), while the FY2025 annual figure was -$4268.0, changed N/A from the prior year.
- Depreciation & Amortization (CF) was -$1330.0 for Q3 2025 at Psyence Biomedical, down from $1016.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1016.0 in Q3 2024 to a low of -$1330.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1,395.22 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 429,663.65 |
| 10 | Regeneron Pharmaceuticals | 66.09 Bn | 57.33 Bn | 3.31 Bn | 123.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,330.00 |
| Sep 30, 2025 | -1,330.00 |
| Sep 30, 2024 | 1,016.00 |
| Sep 30, 2024 | 1,016.00 |